- Gardner-test - mailman.xmission.com

Re: Credit Application Declined
by Dale Foley 05 Mar '04

05 Mar '04

Are you drowning in debt? Here's what we can do for YOU!! Terminate your credit card debt! Allow you to stop making payments immediately! Obtain a ZERO BALANCE statement from your creditors! Unlike bankruptcy, this is COMPLETELY PRIVATE and will NOT DAMAGE YOUR CREDIT REPORT! Request your FREE CONSULTATION now! http://www.cutdebt4all.biz/ stop http://www.cutdebt4all.biz/1.htm incest opportune quicklime crunch tientsin ordinance troll dishevel makeup zone cargoes glimmer clarendon sweatshirt trouble potassium synonym swigging widgeon acerbic destiny kern cominform raillery regress demonic marguerite thayer begonia lever zoo dispensary lawsuit isaac silvery ambassador goof zgy qggg severaltytendon jawbone sleight mere bauer bateau belladonna calendrical argo baleful apposition competitive coot hunter hardbake straddle caucasian

1 0

[Gardner-test] Great News for NRIP - $1.2M contract - it will go through the roof
by carolyn_hammill＠4funlsi.com 04 Mar '04

04 Mar '04

$1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick ************************************************************************** $1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick !!!!!!!!The Stock has VERY TIGHT FLOAT - ONLY 200 000 shares !!!!!! A few days ago NRIP reported January and February sales total more than $250,000.00, a 75% increase over the same period last year. ************************************************************************* Congratulations to all members who took advantage of our February Stock Pick GETC - The stock was profiled at 18 cents and reached 98 cents on Friday ************************************************************************* -------------------------------------------------- The hottest stock for the FIRST week of March NRIP - NRIP - NRIP - NRIP - NRIP ++ Top March Trading Alert ++ Company Profile Nutri Pharmaceuticals Research, Inc. Symbol: NRIP Current Price: $1.01 ONCE AGAIN - The Stock has VERY TIGHT FLOAT - ABOUT 200 000 shares SPECULATIVE NEAR TERM TARGET PRICE - $2.8 SPECULATIVE LONG TERM TARGET PRICE - $3.0 A few Reasons to own NRIP - Feb 24, 2004 NRIP announced the substantial increase of O2P(TM) orders January and February sales total more than $250,000.00, a 75% increase over the same period last year. - Feb 27, 2004 NRIP.PK is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars - Their Facilities include In-house research and development allow tailored formulations to your requirements A granulator with a capacity of 500 kilos A blender with a capacity of 800 kilos 3 encapsulation machines capable of 75,000 capsules per hour 4 tablet presses capable of a half million tablets per hour Tablet coating is available Transformation of liquids to powder (The O2P Process) A complete bottling and packaging department -------------------READ READ READ---------------------- Nutri Pharmaceuticals Research, Inc. Announces 1.2 Million Dollar Sale ------------------------------------------------------- LAS VEGAS, Feb 27, 2004 (BUSINESS WIRE) -- Nutri Pharmaceuticals Research, Inc. (Pink Sheets:NRIP.PK), is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. The contract calls for the monthly processing and shipment of two or more tons of Vitamin E powder. This agreement, valued at minimum 1.2 million dollars, will be a significant addition the company's yearly sales. "This contract, together with the recently announced acceptance of Kenko Corporation, of Tokyo, as our exclusive Japanese Distributor for the Company's O2PT products should further strengthen the Company's bottom line," Said Godfrey Yew, president and CEO of Nutri Pharmaceuticals Research. About Kenko: Kenco Corporation is a major Japanese manufacturer, distributor and world-wide exporter of chemicals, allied products, pharmaceuticals and supplementary nutrients. Last year it had global sales of 150 million dollars. About Nutri Pharmaceuticals Research Inc.: Nutri Pharmaceuticals Research Inc. is the world's leading processor of oil-to-powder. The company's proprietary O2P process transforms most edible oils into a free-flowing powder form that preserves more of the natural active components than other processes. Such powdered oils have application and demand in the food ingredient, livestock feeds, pet foods, nutraceutical, cosmetic and pesticide market sectors. We are also a wholesale private label manufacturer of vitamins and health food supplements. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and implementation thereof. --------------- Disclaimer --------------- Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $700 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. To be removed from further emails send email to : --------------------- $1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick ************************************************************************** $1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick !!!!!!!!The Stock has VERY TIGHT FLOAT - ONLY 200 000 shares !!!!!! A few days ago NRIP reported January and February sales total more than $250,000.00, a 75% increase over the same period last year. ************************************************************************* Congratulations to all members who took advantage of our February Stock Pick GETC - The stock was profiled at 18 cents and reached 98 cents on Friday ************************************************************************* -------------------------------------------------- The hottest stock for the FIRST week of March NRIP - NRIP - NRIP - NRIP - NRIP ++ Top March Trading Alert ++ Company Profile Nutri Pharmaceuticals Research, Inc. Symbol: NRIP Current Price: $1.01 ONCE AGAIN - The Stock has VERY TIGHT FLOAT - ABOUT 200 000 shares SPECULATIVE NEAR TERM TARGET PRICE - $2.8 SPECULATIVE LONG TERM TARGET PRICE - $3.0 A few Reasons to own NRIP - Feb 24, 2004 NRIP announced the substantial increase of O2P(TM) orders January and February sales total more than $250,000.00, a 75% increase over the same period last year. - Feb 27, 2004 NRIP.PK is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars - Their Facilities include In-house research and development allow tailored formulations to your requirements A granulator with a capacity of 500 kilos A blender with a capacity of 800 kilos 3 encapsulation machines capable of 75,000 capsules per hour 4 tablet presses capable of a half million tablets per hour Tablet coating is available Transformation of liquids to powder (The O2P Process) A complete bottling and packaging department -------------------READ READ READ---------------------- Nutri Pharmaceuticals Research, Inc. Announces 1.2 Million Dollar Sale ------------------------------------------------------- LAS VEGAS, Feb 27, 2004 (BUSINESS WIRE) -- Nutri Pharmaceuticals Research, Inc. (Pink Sheets:NRIP.PK), is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. The contract calls for the monthly processing and shipment of two or more tons of Vitamin E powder. This agreement, valued at minimum 1.2 million dollars, will be a significant addition the company's yearly sales. "This contract, together with the recently announced acceptance of Kenko Corporation, of Tokyo, as our exclusive Japanese Distributor for the Company's O2PT products should further strengthen the Company's bottom line," Said Godfrey Yew, president and CEO of Nutri Pharmaceuticals Research. About Kenko: Kenco Corporation is a major Japanese manufacturer, distributor and world-wide exporter of chemicals, allied products, pharmaceuticals and supplementary nutrients. Last year it had global sales of 150 million dollars. About Nutri Pharmaceuticals Research Inc.: Nutri Pharmaceuticals Research Inc. is the world's leading processor of oil-to-powder. The company's proprietary O2P process transforms most edible oils into a free-flowing powder form that preserves more of the natural active components than other processes. Such powdered oils have application and demand in the food ingredient, livestock feeds, pet foods, nutraceutical, cosmetic and pesticide market sectors. We are also a wholesale private label manufacturer of vitamins and health food supplements. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and implementation thereof. --------------- Disclaimer --------------- Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $700 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. To be removed from further emails send email to : ---------------------

1 0

Cyber Solutions
by Cyber Solutions 04 Mar '04

04 Mar '04

1 0

real, certifiable university degrees for sale
by Ashlee Mead 04 Mar '04

04 Mar '04

1 0

Keep More Cash Each Month !
by Jay Flanagan 04 Mar '04

04 Mar '04

1 0

Real Sweet Deal ! Buy Without Cash !
by Your Info Presents 03 Mar '04

03 Mar '04

1 0

Consolidate a 1st and 2nd mortgage
by Alana Jones 02 Mar '04

02 Mar '04

Want to pay less for your home? Found a home and now you need a mortgage? Find lenders ready to finance your home loan today! We have a network of 3000 lenders Request your FREE CONSULTATION now! http://www.cutdebt4all.biz/input.php stop http://www.cutdebt4all.biz/1.htm adam clara axis trudy goblet effluvium worst archival envoy obedient cautious participant pius bridgehead brethren crab evil cavil died blab rectangular extempore astraddle bid chloroplast waspish dilettante sneaky classificatory roustabout disparage fkb iowi hornblowerbuckwheat postposition defensive supple blasphemous constitutive stiletto faraday immiscible imp cobblestone gubernatorial attest workpiece algebraic maxima rodney bran drift fairy

1 0

Gardner-test, Super-VÎÀGRÀ at Super-ÐÎSC0ÜNT
by Pdad88 02 Mar '04

02 Mar '04

Hello! Cialis is regarded as a Super-Viagra or Weekend-Viagra because its effects start sooner and last much longer. http://www.medz4cheap.com/cia/?toougly * LONGER LIFE Up to 36 hours compared to 4 hours for viagra * ACTS FASTER from as little as 15 minutes compared to 60 minutes for viagra * BEST SEX EVER solid erection and only whenever you need it. With cialis YOU are in control "Cialis works in 15 minutes and lasts for 36 hours giving you strong healthy erections whenever you want or need them!" Generic cialis (Regalis), at cheap prices BECAUSE AVAILABLE DIRECTLY FROM MANUFRACTURE AT A FRACTION OF THE COST http://www.medz4cheap.com/cia/?toougly Most places charge $20, we charge $2.45. Quite a difference. thanks If you are not interested in our email http://www.medz4cheap.com/off.html

1 0

This is a VERY different affiliate program
by Roland Bautista 01 Mar '04

01 Mar '04

1 0

[Gardner-test] Subscribers benefit from our special stock updates j q
by Juanita Metz 01 Mar '04

01 Mar '04

Wall Street Financial Times Newsletter Specializing in Undervalued Small Cap Stocks for Immediate Breakout We have the #1 track record for our picks in 2004: GETC at .12 Currently .50 High .68 UP 467% TLPE at 1.12 Currently 3.35 High 4.40 UP 293% SWYC at .18 Currently .71 High .81 UP 350% DNYY at .47 Currently 1.42 High 1.85 UP 294% Immediate Investor Recommendation Our Hottest Sales and Earnings Play Projected to Triple in 7 Days: Life Energy and Technology Holdings, Inc. (OTCBB: LETH) Price--- 1.35 Sales Orders Received '03--- over $150 Million +300% growth vs. '02 Est. Sales Growth '04--- +165% Results from latest 10-Q: Total Assets--- 36.8 million vs. 16.8 million Cash--- 23.4 million vs. deficit Shareholders Equity--- 12.0 million vs. 2.2 million Shares Outstanding--- 29 mill Est. Shares in Float--- 7 mill Proj. Value Per Share--- 3.25 -- 3.50 Rating--- Urgent Buy LETH is thriving as an emerging world leader in the conversion of waste materials into electrical energy by utilizing their Biosphere Process System, making them the hottest undervalued stock at this price level where shares are ready to explode on huge investor attention. Sales have rocketed beyond all estimates for LETH with no signs of slowing. The numbers continue to stack-up as sales orders for the Biosphere exceed $150 Million over the past year while the stock price doesn't yet reflect the appearance of these impressive figures on an upcoming balance sheet. We are not the first to uncover this phenomenon as the stock is under accumulation, but we are acting aggressively on this recently filed data. The unique proprietary technology of the Biosphere fills an urgent worldwide need for cost-effective renewable energy sources and a corresponding universal need to solve critical problems in the disposal of waste. The Biosphere System provides the highest level of innovative technology while securing worldwide acceptance for a revolutionary product designed to significantly impact the global waste problem while simultaneously generating electricity. The Biosphere System enables LETH to draw revenue from the disposal of various types of waste at 5 to 7 tons per hour including such materials as: Municipal Solid Waste, refinery wastes, agricultural surpluses or effluents, medical waste, industrial waste, shale oil, sour natural gas, and the huge market of used tires are all converted in the Biosphere Process. LETH also profits from the sale of electricity created from the waste conversion on a continuous basis by generating 5 to 10 mega-watts per hour of electricity which is then sold to replenish the local or national grid. LETH is an alliance partner with Tetra Tech, Inc. (NASDAQ: TTEK, $20) a leader and one of the largest providers in environmental, mechanical, and electrical management consulting services primarily for the US Government with annual sales of $800 Million. Tetra Tech will coordinate permitting, installation and continuous worldwide monitoring of the Biosphere Process System for LETH. Tetra Tech is now in the process of obtaining Department of Environmental Quality permitting for the Biosphere Process in the state of Louisiana. This is a monumental event for LETH which opens the floodgates for major project revenues in Louisiana while having a parallel effect on LETH stock in the form of a huge near-term announcement. LETH has begun to catch the profit-making attention of investors by embracing a major foothold on the global waste problem while a major push for generating electricity from alternative sources continues to be the hot topic due to shortages and massive power failures. LETH contains all the ingredients for major profits as global demand to solve two crisis areas, waste and electrical energy, reaches unprecedented levels. We view this perfectly timed convergence of events as the catalyst for additional contracts that will perpetuate the shattering of the Company's own sales records. We are seeing substantial gains for early investors in a ground floor opportunity that carries our highest rating for short-term trading profits. Required LETH information: Certain statements contained in this newsletter may be forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such terms as "expect", "believe", "may", "will", and "intend" or similar terms may identify these statements We are not a registered investment advisor or a broker dealer. This is not an offer to buy or sell securities. No recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies. This is an independent electronic publication that was paid five thousand dollars by an unaffiliated third party for the preparation of this company information. Be advised that investments in companies profiled are considered to be high-risk and use of the content provided is for information purposes only. If anyone decides to act as an investor they are advised not to invest without the proper guidance from a financial advisor or a registered financial broker. If any party decides to participate as an investor then it will be that investor's sole risk. Be advised that the purchase of such high-risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided in this newsletter as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form their own opinion regarding investing in the profiled companies. Factual statements made about the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. All information provided about the profiled companies may include information provided by outside sources, such as research reports, public filings, and information provided by management of the profiled company. wvinn pv dshinibhj k

1 0